January 8, 2026
1 min read

Acuitas takes majority stake in Montreal-based RNA construct manufacturer

Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics in a move to scale the latter’s operations around high-end RNA constructs used to produce cutting-edge gene therapies.

Leave a Reply

Your email address will not be published.

Previous Story

Statement from the Academy of Nutrition and Dietetics on the Release of the Dietary Guidelines for Americans, 2025–2030

Next Story

STAT+: Slashing of U.S. vaccine schedule creates new uncertainty on manufacturers’ legal protections

Previous Story

Statement from the Academy of Nutrition and Dietetics on the Release of the Dietary Guidelines for Americans, 2025–2030

Next Story

STAT+: Slashing of U.S. vaccine schedule creates new uncertainty on manufacturers’ legal protections

Latest from Blog

NEWS CENTER Maine

Through in-depth storytelling, through direct contact on digital on social platforms, through long-standing community service programs like Coats & Toys for Kids, Project Heat and Buddy to Buddy, NEWS CENTER Maine is
Go toTop